Biotechnology

With compelling Phase 2b survival data, NeuroSense is advancing its multi-target ALS drug to a pivotal Phase 3 trial. A deep dive into the science and strategy.

With a key NSF grant and promising large-animal data, Endure Biotherapeutics' engineered 'native' bacteria may rewrite the playbook for PKU and beyond.

A Chinese AI innovator and a new European biotech just sealed a massive deal. It’s a blueprint for the future of medicine, where technology and strategy unite for patients.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

In a cooling life science real estate market, a major lease for advanced manufacturing highlights the rise of radiopharmaceuticals and Boston's enduring industrial might.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

With new funding from top VCs, DropGenie is shrinking gene editing to power the next wave of AI-driven drug discovery using precious patient cells.

Israel's Biond Biologics hires Dr. Giovanni Selvaggi, a seasoned drug developer, as CMO. The move signals a strategic shift to accelerate its unique 'first-in-class' immunotherapies through late-stage trials.

A startup just raised $5M for an AI that teaches cells to be better factories. It's a glimpse into a future of cheaper, faster advanced medicines for all.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.

Genialis's new BioBridge platform uses AI to de-risk the $137B flow of oncology drugs from China to the West, a critical test of resilience.

Sanofi taps AI-native biotech expert Paulo Fontoura to lead its global R&D, a high-stakes move to accelerate drug discovery after recent pipeline disappointments.

A new partnership between Pirche and Natera promises to connect pre-transplant risk analysis with post-transplant monitoring, ushering in an era of truly personalized care.

A new index reveals pharma's $8B ad spend fails to buy AI visibility. Eli Lilly and Novo Nordisk lead as AI follows patient research, not TV spots.

With no approved drugs for the Bundibugyo Ebola outbreak, 101 Therapeutics releases un-reviewed data, forcing a global health showdown between speed and safety.

Straive's acquisition of NextGen Invent isn't just another deal; it's a strategic strike to dominate the AI operationalization market. Here's why.

At BIO 2026, Fapon Group unveils a novel strategy combining T-cell engagers and in vivo CAR-T to target complex diseases. What does this mean for the future?

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

As global supply chains shift, a conference in Montreal highlights a crucial trade realignment. But are Canadian firms ready to seize the massive EU opportunity?